

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Antengene Corporation Limited

德琪醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6996)

VOLUNTARY ANNOUNCEMENT

INCREASE IN SHAREHOLDING BY FOUNDER, CEO, CHAIRMAN AND OTHER MANAGEMENT

This announcement is made by Antengene Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest updates in relation to the Group.

The board (the “**Board**”) of directors of the Company (the “**Director(s)**”) was informed by Dr. Jay Mei (“**Dr. Mei**”), the founder, an executive Director and the chief executive officer of the Company and chairman of the Board, that on March 23 and 24, 2026, Dr. Mei purchased an aggregate of 200,000 ordinary shares of the Company (the “**Shares**”) through an entity controlled by him, representing approximately 0.029% of the total issued Shares (excluding the 202,500 treasury Shares), in the open market at an average price of approximately USD\$0.512 (being equivalent to approximately HK\$3.99 at an exchange rate of 7.8) per Share. Immediately following the purchase, by virtue of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”), Dr. Mei is interested in or deemed to be interested in an aggregate of 184,467,994 Shares, representing approximately 27.158% of the total issued Shares (excluding the 202,500 treasury Shares) as at the date of this announcement.

The Board was further informed by Mr. Donald Andrew Lung (“**Mr. Lung**”), an executive Director and the chief financial officer of the Company, that on March 23 and 24, 2026, Mr. Lung purchased an aggregate of 502,500 Shares, representing approximately 0.074% of the total issued Shares (excluding the 202,500 treasury Shares), in the open market at an average price of approximately HK\$4.006 per Share. Immediately following the purchase, by virtue of Part XV of the SFO, Mr. Lung is interested in or deemed to be interested in an aggregate of 4,482,500 Shares, representing approximately 0.66% of the total issued Shares (excluding the 202,500 treasury Shares) as at the date of this announcement.

The Board was also informed by Mr. Yang Cao (“**Mr. Cao**”), the corporate vice president and board secretary of the Company, that he acquired Shares in the open market on March 23 and 24, 2026 for an aggregate consideration of HK\$1.042 million.

The total consideration paid by Dr. Mei, Mr. Lung and Mr. Cao for the acquisition of Shares in the open market was HK\$3.853 million in aggregate.

As advised by Dr. Mei, Mr. Lung and Mr. Cao, the purchases were made based on their strong confidence in the Group's long-term investment value, robust research and development capabilities and ability to drive continued innovation. They believe that the Group is well-positioned to advance its pipeline and deliver sustainable long-term growth.

Subject to compliance with applicable laws and regulatory requirements, they do not rule out the possibility of further increasing their shareholding in the Company as and when appropriate. The Board considers that such purchases reflect their firm confidence in the future prospects of the Company and their long-term commitment to its development.

Based on the information available to the Company and to the knowledge of the Board, following the completion of the increase in shareholding and as at the date of this announcement, the Company has continued to maintain a sufficient public float of its issued Shares in compliance with Rule 8.08 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”); and the increase in shareholding was conducted in compliance with the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 to the Listing Rules adopted by the Company.

Shareholders of the Company and potential investors are advised to exercise due caution when dealing in the securities of the Company.

By the order of the Board
Antengene Corporation Limited
Dr. Jay Mei
Chairman

Hong Kong, March 25, 2026

As at the date of this announcement, the board of directors comprises Dr. Jay Mei and Mr. Donald Andrew Lung as executive Directors; and Ms. Jing Qian, Mr. Sheng Tang and Dr. Rafael Fonseca as independent non-executive Directors.

About Antengene

Antengene Corporation Limited (“**Antengene**”, SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans from preclinical to commercial stages and includes several in-house discovered programs, including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), and ATG-125 (B7-H3 x PD-L1 bispecific ADC).

Antengene has also developed AnTenGager™, a proprietary T cell engager 2.0 platform featuring “2+1” bivalent binding for low expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform’s broad applicability across autoimmune disease, solid tumors and hematological malignancies, with programs targeting CD19 x CD3 (ATG-201 for B cell-related autoimmune diseases; partnered with UCB), CDH6 x CD3 (ATG-106 for ovarian cancer and kidney cancer), ALPPL2 x CD3 (ATG-112 for gynecological tumors, digestive system malignancies, bladder cancer and NSCLC), LY6G6D x CD3 (ATG-110 for microsatellite-stable colorectal cancer), GPRC5D x CD3 (ATG-021 for multiple myeloma), LILRB4 x CD3 (ATG-102 for acute myeloid leukemia and chronic myelomonocytic leukemia) and FLT3 x CD3 (ATG-107 for acute myeloid leukemia).

To date, Antengene has obtained 32 investigational new drug (IND) approvals in the U.S. and Asia, and obtained new drug application (NDA) approvals in 10 Asia Pacific markets. Its lead commercial asset, XPOVIO® (selinexor), is approved in the Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia, and has been included in the national insurance schemes in five of these markets (Mainland China, Taiwan China, Australia, South Korea and Singapore).

Forward-looking statements

The forward-looking statements made in this announcement relate only to the events or information as of the date on which the statements are made in this announcement. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this announcement completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this announcement, statements of, or references to, our intentions or those of any of the Directors or the Company are made as of the date of this announcement. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company’s annual results announcement for the year ended December 31, 2025, and the documents subsequently submitted to The Stock Exchange of Hong Kong Limited.